A NOTE ON THE BEHAVIOR OF THE KAPLAN-MEIER ESTIMATOR UNDER GENERAL CENSORSHIP

Jiantian Wang (U. S. A.)

Received December 17, 2007

References:

[1] H. Bang and A. A. Tsiatis, Estimating medical costs with censored data, Biometrika 87 (2000), 329-343. [2] C. L. Chiang, Introduction to Stochastic Processes in Biostatistics, Wiley, New York, 1968. [3] T. R. Fleming and D. P. Harrington, Counting Processes and Survival Analysis, Wiley, New York, 1991. [4] T. R. Fleming and D. Y. Lin, Survival analysis in clinical trials: past development sand future directions, Biometrics 56 (2000), 971-983. [5] R. D. Gelber, R. S. Gelman and A. Goldhirsch, A quality-of-life-oriented endpoint for comparing therapies, Biometrics 45 (1989), 781-795. [6] J. D. Kalbfleisch and R. L. Prentice, The Statistical Analysis of Failure Time Data, Wiley, New York, 1980. [7] E. L. Kaplan and P. Meier, Nonparametric estimation from incomplete observations, J. Amer. Statist. Assoc. 53 (1958), 457-481. [8] K. M. Leung, R. M. Elashoff and A. A. Afifi, Censoring issues in survival analysis, Ann. Rev. Public Health 18 (1997), 83-104. [9] D. Oakes, Biometrika centenary: survival analysis, Biometrika 88 (2001), 99-142. [10] J. A. Wellner, Asymptotic optimality of the product limit estimator, Ann. Statist. 10 (1982), 595-602.

Keywords and phrases: Kaplan-Meier estimator, survival function, overestimation, underestimation.